MENU
+Compare
CANC
ETF ticker: NASDAQ
AS OF
Apr 2, 04:59 PM (EDT)
Price
$23.95
Change
+$0.50 (+2.13%)
Net Assets
62.3M

CANC stock forecast, quote, news & analysis

The investment seeks to provide long-term growth... Show more

Category: #Health
CANC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Ad is loading...
A.I.Advisor
a Summary for CANC with price predictions
Apr 01, 2025

CANC's RSI Indicator descending into oversold zone

The RSI Indicator for CANC moved into overbought territory on April 01, 2025. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CANC advanced for three days, in of 100 cases, the price rose further within the following month. The odds of a continued upward trend are .

CANC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 67 cases where CANC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on March 26, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on CANC as a result. In of 23 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for CANC turned negative on March 25, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 13 similar instances when the indicator turned negative. In of the 13 cases the stock turned lower in the days that followed. This puts the odds of success at .

CANC moved below its 50-day moving average on March 25, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for CANC crossed bearishly below the 50-day moving average on March 14, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 5 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CANC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Merck & Co (NYSE:MRK), AstraZeneca PLC (NASDAQ:AZN), Bristol-Myers Squibb Co (NYSE:BMY), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), Illumina (NASDAQ:ILMN), Exact Sciences Corp (NASDAQ:EXAS), Incyte Corp (NASDAQ:INCY), Moderna (NASDAQ:MRNA), Exelixis (NASDAQ:EXEL).

Industry description

The investment seeks to provide long-term growth. Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from oncology. The fund is non-diversified.

Market Cap

The average market capitalization across the Tema Oncology ETF ETF is 24.71B. The market cap for tickers in the group ranges from 3.51M to 331.75B. MRK holds the highest valuation in this group at 331.75B. The lowest valued company is NOVN at 3.51M.

High and low price notable news

The average weekly price growth across all stocks in the Tema Oncology ETF ETF was 2%. For the same ETF, the average monthly price growth was 7%, and the average quarterly price growth was 96%. GILD experienced the highest price growth at 3%, while MRSN experienced the biggest fall at -25%.

Volume

The average weekly volume growth across all stocks in the Tema Oncology ETF ETF was 13%. For the same stocks of the ETF, the average monthly volume growth was -21% and the average quarterly volume growth was 66%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 54
P/E Growth Rating: 75
Price Growth Rating: 70
SMR Rating: 84
Profit Risk Rating: 80
Seasonality Score: -11 (-100 ... +100)
View a ticker or compare two or three
CANC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
United Satets
Phone
N/A
Web
www.tema.co